Merck & Co.’s Covid-19 pill will likely still get U.S. authorization despite disappointing efficacy data and concerns raised by regulators, Morgan Stanley analysts predicted.
Merck shares fell 3.8% Friday after the release of data showing molnupiravir was less effective than previously reported, and as the Food and Drug Administration raised concerns about its safety and long-term effectiveness.
